-
Cost per Responder Analysis of Certolizumab Pegol vs. Adalimumab in Patients With Moderate to Severe Active Rheumatoid Arthritis and High Rheumatoid Factor Levels: A Payer Perspective From France, Germany, Italy, and United Kingdom
Sep 9, 2025, 16:22 PM -
Health Economic Analysis of Risk- and Age-Based Pneumococcal Vaccination With PCV21 vs. PCV20 in France
Sep 9, 2025, 16:22 PM -
Impact of the Severity of Disease-Related Malnutrition on Healthcare Resource Utilization in Pediatric Patients 1 Year and Older
Sep 9, 2025, 16:22 PM -
Costs Associated With the Treatment of Surgical Site Infections in Solid Organ Transplant Recipients: A Scoping Review
Sep 9, 2025, 16:22 PM -
Feasibility Evaluation of Claims Database: Best Practices and Case Study for a Comparative Analysis of Robotic-Assisted Colorectal Surgery in Germany
Sep 9, 2025, 16:22 PM -
Inequity in Public Healthcare Utilization Among Persons With Disabilities in Bangladesh: A Benefit Incidence Analysis
Sep 9, 2025, 16:22 PM -
Postmarketing Safety Analysis of Nebivolol in Real-World Settings Using Bioinformatics and Disproportionality Analysis With FDA Adverse Event Reporting System (FAERS) Data
Sep 9, 2025, 16:22 PM -
Evaluating the Effectiveness of Interventions to Reduce Gender Disparities in Healthcare: An Overview of Literature Reviews
Sep 9, 2025, 16:22 PM -
Transforming Patient Journeys With Agentic AI
Sep 9, 2025, 16:22 PM -
AI-Driven Simulation of FDA DCOA Review to Inform Evidence Planning and Regulatory Strategy
Sep 9, 2025, 16:22 PM -
Healthcare Resource Utilization (HCRU) and Associated Costs in Patients With Advanced Merkel Cell Carcinoma (aMCC) in Germany: Analysis From the MCC TRIM Registry Study
Sep 9, 2025, 16:22 PM -
A Systematic Review of Using Social Return on Investments Within Healthcare Service Evaluations: Methodological Opportunity and Challenges
Sep 9, 2025, 16:22 PM -
Persistence of Anticholinergic Agents in Patients With Overactive Bladder: A Cohort Study From the French National Health Insurance Claim Database (SNDS)
Sep 9, 2025, 16:22 PM -
Gaps in JCA Guidance for Systematic Literature Reviews: A Comparative Review with Cochrane, EUnetHTA, and Major HTA Agencies' Standards
Sep 9, 2025, 16:22 PM -
Budget Impact Analysis of Direct Oral Anticoagulants vs. Vitamin K Antagonists in Algeria: A Public Payer Perspective
Sep 9, 2025, 16:22 PM -
Estimating the Eligible Population for Anti-Amyloid Therapy in Finland
Sep 9, 2025, 16:22 PM -
Public Health Impact of Herpes Zoster Vaccination in Immunocompromised Adults Aged 18-49 Years in the United Kingdom
Sep 9, 2025, 16:22 PM -
Estimating the Future Burden of Unvaccinated Girls Against Human Papilloma Virus (HPV) in Europe: A Modeling Study
Sep 9, 2025, 16:22 PM -
Real-World Assessment Process to Identify Fit-for-Purpose Data Sources to Meet Milestones for Post-Marketing Requirements (PMR), Post Authorization Safety Studies (PASS), and Health Technology Assessment (HTA) Submissions Utilizing Source Exploration...
Sep 9, 2025, 16:22 PM -
Quantifying the Fiscal Benefits of Obesity Prevalence Reduction in China: A Public Economic Perspective
Sep 9, 2025, 16:22 PM
